N-(2-carboxyethyl)-N-octyl-β-alanine

Endpoint summary

Description of key information

The oral LD50 study on Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, CAS No 94441-92-6 has reliability rating 2 and the procedure used meets the requirements of the limit test for acute oral toxicity described by the OECD Guideline 401. The results of this GLP compliant study indicate that the test material has little toxic effect when administered as a single oral dose to the rat at a dose level of 5000 mg/kg bw. The test material used consists of 40% active ingredient and 60% water. As the oral LD50 of the product is > 5000 mg/kg bw, the LD50 of the active ingredient is considered to be > 2000 mg/kg bw.

The dermal LD50 study (OECD Guideline 402) on Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, CAS No 94441-92-6 is performed according to GLP and has reliability rating 1. It is therefore considered acceptable for classification and labelling purposes. The LD50 of the active ingredient is considered to be > 2000 mg/kg bw, and it does not have to be classified and has no obligatory labelling requirement for acute dermal toxicity.

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

February 1987

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: No data on batch no and composition is included in the study report. Internal data on composition is available. Study according to guideline/standards.

Qualifier:

according to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

Deviations:

no

GLP compliance:

yes

Test type:

standard acute method

Limit test:

yes

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River (UK) Ltd., Margate, Kent, UK
- Age at study initiation: no info except for young adult
- Weight at study initiation: 91 ± 6 g (males), 90 ± 3 g (females)
- Fasting period before study: overnight prior to dosing
- Housing: five per sex in polypropylene cages
- Diet (e.g. ad libitum): ad lib
- Water (e.g. ad libitum): ad lib
- Acclimation period: 7 days


ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-22
- Humidity (%): 49-61
- Air changes (per hr): no info
- Photoperiod (hrs dark / hrs light): 12/12


IN-LIFE DATES: From: 6 To: 20 February 1987

Route of administration:

oral: gavage

Vehicle:

water

Details on oral exposure:

VEHICLE
- Concentration in vehicle: not indicated
- Amount of vehicle (if gavage): 20 mL/kg
- Justification for choice of vehicle: no info

MAXIMUM DOSE VOLUME APPLIED: 20 mL/kg

DOSAGE PREPARATION (if unusual): the test material was neutralised to a pH of 7.0 using 1.0 M citric acid and then diluted with
distilled water to give a dose volume of 20 mL/kg at a dose level of 5000 mg/kg

Doses:

5000 mg/kg bw

No. of animals per sex per dose:

5

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Frequency of observations and weighing:frequently after dosing and then daily; BW weekly
- Necropsy of survivors performed: yes
- Other examinations performed: no

Statistics:

Not required

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 5 000 mg/kg bw

Remarks on result:

other: no mortality

Mortality:

None

Clinical signs:

other: One female and five male animals exhibited piloerection within one hour of dosing, one male animal also exhibiting perinasal staining.The animals had fully recovered by Day 2 (Day 1 is day of dosing).

Gross pathology:

No abnormalities noted

Other findings:

No

Interpretation of results:

Category 5 based on GHS criteria

Remarks:

Migrated information

Conclusions:

The test material used consists of 40% active ingredient and 60% water. As the oral LD50 of the product is > 5000 mg/kg bw, the LD50 of the active ingredient is considered to be > 2000 mg/kg bw. Therefore the active ingredient is classified as Category V, according to OECD-GHS criteria.

Executive summary:

The toxicity of the test material was assessed following its oral administration to a group of five male and five female rats. The procedure used meets the requirements of the limit test for acute oral toxicity described by the OECD (Organisation for Economic Co-operation and Development). Following overnight fasting rats were administered the test material, by peroral injection, at a dose level of 5000 mg/kg bw. All animals were observed for a fourteen day period for any signs of toxicity or other effects of treatment. One female and five male animals exhibited piloerection within one hour of dosing, one male animal also exhibiting perinasal staining. The animals had fully recovered by Day 2 (Day 1 is day of dosing). No other effects to treatment were observed throughout the duration of the study and no abnormalities were detected at necropsy. The results of this study indicate that the test material, Ampholak YJH, has little toxic effect when administered as a single oral dose to the rat at a dose level of 5000 mg/kg bw. The test material used consists of 40% active ingredient and 60% water. As the oral LD50 of the product is > 5000 mg/kg bw, the LD50 of the active ingredient is considered to be > 2000 mg/kg bw. Therefore it is classified as Category V, according to OECD-GHS criteria.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Acute toxicity: via inhalation route

Link to relevant study records

Reference

Endpoint:

acute toxicity: inhalation

Data waiving:

study scientifically not necessary / other information available

Justification for data waiving:

other:

Clinical signs:

other:

Endpoint conclusion

Endpoint conclusion:

no study available

Acute toxicity: via dermal route

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Additional information

Two acute studies are available on Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, CAS No 94441-92-6, one on acute oral toxicity and one on acute dermal toxicity.

 

The oral LD50 study on Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, CAS No 94441-92-6 has reliability rating 2 and the procedure used meets the requirements of the limit test for acute oral toxicity described by the OECD Guideline 401. The reliability rating of 2 is based on the fact that there is no information on batch number or composition of the substance within the report. Internal data on composition is available, and the result from this study is considered to give a true evaluation of the acute oral toxicity potential of the substance. The results of this GLP compliant study indicate that the test material has little toxic effect when administered as a single oral dose to the rat at a dose level of 5000 mg/kg bw. The test material used consists of 40% active ingredient and 60% water. As the oral LD50 of the product is > 5000 mg/kg bw, the LD50 of the active ingredient is considered to be > 2000 mg/kg bw.

The dermal LD50 study (OECD Guideline 402) on Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, CAS No 94441-92-6 is performed in 2012 according to GLP and has reliability rating 1. It is therefore considered reliable to use for classification and labelling purposes. The LD50 of the active ingredient is considered to be > 2000 mg/kg bw, and it does not have to be classified and has no obligatory labelling requirement for acute dermal toxicity

 

Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate), CAS 94441-92-6 it is a paste with a low vapour pressure of 1.5 mPa at 20°C and therefore inhalation exposure is unlikely. Data on acute inhalation is lacking, but the low potential for inhalation exposure means this is not required.

Justification for selection of acute toxicity – oral endpoint

The available study on Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, CAS No 94441-92-6, is acceptable for classification and labelling purposes being of Klimisch 2 validity. The LD50 of the active ingredient is considered to be > 2000 mg/kg bw, and it is classified as Category V, according to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2011).

Justification for selection of acute toxicity – inhalation endpoint

No inhalation LC50 data is available for Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate), CAS 94441-92-6,  however it is a paste with a low vapour pressure of 1.5 mPa at 20°C, significant exposure to vapours would not be expected at ambient temperatures so the lack of an inhalation LD50 is not considered significant as inhalation is not an expected route of exposure.

Justification for selection of acute toxicity – dermal endpoint

The available study on Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, CAS No 94441-92-6, is acceptable for classification and labelling purposes being of Klimisch 1 validity. The LD50 of the active ingredient is considered to be > 2000 mg/kg bw, and it does not have to be classified and has no obligatory labelling requirement for acute dermal toxicity according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2011), nor the Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures.

Justification for classification or non-classification

Although the acute oral study has a reliability of 2, it is considered to be correct and based upon the classification criteria according to the Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008, Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate), CAS 94441-92-6 does not have to be classified and labeled with respect to acute oral toxicity in the rat.

 

Based upon the classification criteria according to the Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008, Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate), CAS 94441-92-6 does not have to be classified and labeled with respect to acute dermal toxicity in the rat.